RBC Capital Reiterates Sector Perform on BioMarin Pharmaceutical, Maintains $66 Price Target

Benzinga Newsdesk www.benzinga.com Positive 75.9%

Neg 0% Neu 0% Pos 75.9%

RBC Capital analyst Luca Issi reiterates BioMarin Pharmaceutical (NASDAQ:BMRN) with a Sector Perform and maintains $66 price target.